Sundar Jagannath, MD

Dr. Jagannath on the Safety Profile of Selinexor in Multiple Myeloma

September 20th 2019

Sundar Jagannath, MD, discusses the use and toxicity profile of selinexor in multiple myeloma treatment.

Dr. Jagannath on Treatment Advances in Transplant-Ineligible Patients With Myeloma

January 22nd 2019

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the progress that has been made in transplant-ineligible patients with multiple myeloma.

Dr. Jagannath on Cancer Proliferation in Multiple Myeloma

December 21st 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

November 29th 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.

Dr. Jagannath on Mechanism of Action of Selinexor in Myeloma

June 16th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the mechanism of action of selinexor and its efficacy in multiple myeloma and other tumor types.

Dr. Jagannath on CAR T-Cell Therapy for Multiple Myeloma

June 9th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.

Dr. Jagannath on Potential of Immunotherapy in Multiple Myeloma

March 27th 2017

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Dr. Jagannath on Role for Two-Drug Combinations, Carfilzomib Triplet in Multiple Myeloma

October 14th 2016

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of Medicine (Hematology and Medical Oncology) at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses induction therapy for multiple myeloma.

Dr. Sundar Jagannath on Three-Drug Regimen for Newly Diagnosed Multiple Myeloma

September 12th 2016

Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

March 21st 2016

Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses upcoming agents in multiple myeloma.

Dr. Jagannath on Sequencing Therapies for Patients With Multiple Myeloma

March 2nd 2016

Sundar Jagannath, MD, director of the Multiple Myeloma Program, professor of Medicine (Hematology and Medical Oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses sequencing challenges with therapies for patients with multiple myeloma.

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

November 18th 2015

Sundar Jagannath, MD, Professor Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the significance of several recent studies in multiple myeloma.

Dr. Jagannath on Immunotherapy in Multiple Myeloma

March 10th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

Dr. Sundar Jagannath Discusses Approval of Lenalidomide in Multiple Myeloma

February 20th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

Dr. Jagannath on Life Expectancy in Myeloma

January 22nd 2013

Sundar Jagannath, MD, Director, Multiple Myeloma Program, The Tisch Cancer Institute at The Mount Sinai Medical Center, details the advances in life expectancy for patients with multiple myeloma.

Dr. Jagannath on Pomalidomide in Multiple Myeloma

December 21st 2012

Sundar Jagannath, MD, discusses the use of pomalidomide (POM) in relapsed or refractory multiple myeloma.

Dr. Jagannath Discusses the VANTAGE Trials

March 12th 2012

Dr. Sundar Jagannath, from Mount Sinai Medical Center, Discusses the VANTAGE Trials

Dr. Jagannath on HDAC Inhibitors for Multiple Myeloma

February 29th 2012

Dr. Sundar Jagannath from the Tisch Cancer Institute Discusses HDAC Inhibitors for Multiple Myeloma